酪酪肽对四氯化碳诱导的大鼠肝纤维化的影响

目的 观察酪酪肽对大鼠实验性肝纤维化的治疗效果,并探讨可能的作用机制,同时,与干扰素和善宁的治疗效果进行对比.方法 用腹部皮下注射四氯化碳诱导大鼠肝纤维化模型.将实验动物随机分为正常对照组、模型组、γ-干扰素治疗组、善宁治疗组、酪酪肽治疗组.连续用药4周.取血分别作肝功能指标及肝纤维化指标的检测.取部分肝组织HE染色法组织切片观察肝脏病理组织学变化,免疫组织化学法检测肝组织转化生长因子(TGFβ1)的表达.结果 各组大鼠血清肝功能指标和肝纤维化指标经t检验后发现,酪酪肽治疗组TBIL、HA及LN与模型组相比,P<0.05,有统计学意义.酪酪肽可以降低肝纤维化积分,并且降低TGFβ1的表达.结论 酪酪肽可以起到抗肝纤维化的作用,并可能通过下调TGFβ1而发挥其作用.

Effect of peptide YY on hepatic fibrosis in rats

OBJECTIVE: To investigate the therapeutic effects of peptide YY against hepatic fibrosis in rats and explore the possible mechanism. METHOD: Rat models of hepatic fibrosis were established with a subcutaneous injection of carbon tetrachloride and randomized into normal control group, model group, peptide YY (PYY)-treated group, octreotide-treated group, and interferon gamma-treated group. Serum levels of the hepatic function indices and hepatic fibrotic index were detected, and the hepatic fibrosis grade was assessed using HE staining. The expression of transforming growth factor beta1 (TGFbeta1) were determined with immunohistochemical staining method. RESULTS: The rats in PYY-treated group showed significantly different serum levels of TBIL, HA and LN from the rats in the model group (P<0.05). PYY significantly reduced hepatic fibrosis scores and lowered TGFbeta1 expression as compared with the model group. CONCLUSIONS: PYY can down-regulate TGFbeta1 expression to inhibit the development of hepatic fibrosis with comparable efficacy with interferon gamma and octreotide.